Use of chemotherapeutic agents

Abstract

The use of chemotherapeutic agents for the preparation of a medicament for the topical and / or local treatment of diseases caused by bacteria and / or for prophylaxis in humans or animals.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional application of U.S. patent application Ser. No. 10 / 168,441, filed on Jun. 21, 2002, which was filed under International Application No. PCT / EP00 / 13155 filed Dec. 22, 2000, which claims priority to German Patent Application 199 62 470.4 filed Dec. 22, 1999 (the entire disclosures of which are incorporated herein by reference).BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention relates to the use of chemotherapeutic agents for the preparation of a medicament for the topical and / or local treatment of diseases caused by bacteria and / or for prophylaxis in humans or animals.[0004]2. Description of Related Art[0005]Bacteria can be the cause of a large number of diseases and can moreover impair wound healing. In the oral region, for example, tooth decay (caries) is caused by microbes specific to the mouth. Oral bacteria convert dietary carbohydrates to acids capable of dissolving ...

AI Technical Summary

Benefits of technology

[0100]It has now been found that topical application of the compounds of formula (I) or formula (II) can also achieve a satisfactory outcome in the therapy of diabetic foot syndrome. This was demonstrated particularly by the fact that, in patients with severe microangiopathies of the feet accompanying diabetic foot syndromes, attempted systemic treatments with Avalox 400 (moxifloxacin) and / or Clont 400 (2-methyl-5-nitro-1H-imidazol-1-ethanol) brought no significant changes in findings since these active ingredients were only able to achieve very low tissue concentrations after systemic administration because of pronounced microangiopathies. Surprisingly, however, topical application of the compounds of formula (I) or formula (II) led to significant improvements in the pathological process. Ulcers of different degrees of severity (D I to D V ulcers) could be treated. Greasy ulcers became clean, encrusted and smaller in size and even healed completely. This treatment was successful after several topical applications of the compounds of formula (I) or formula (II) at weekly intervals, said compounds being applied to the wound directly in dissolved form or, for example, as a gel or by means of impregnated compresses or dressings. These compounds of formula (1) or formula (II) can be applied to the wound in concentrations of 0.005 mg / ml to 200 mg / ml, preferred concentrations for solutions or gels being those ranging from 0.1 to 150 mg / ml. In the case of impregnated compresses or dressings, gelatinous forms of administration can be used in concentrations of 25-150 mg / ml.

Problems solved by technology

The particular problems associated with treatment of the pulp are the small lymph supply, its position as a terminal organ with a small collateral circulation, and the influence of external stimuli given its location in a rigid, inflexible cavity.

The particular problem associated with the diagnosis of a pulp disease is that the histological and clinical pictures are often quite different.

As pain is sensed and interpreted differently by different patients, there is always the risk of a false diagnosis.

Under the conventional treatment, there is then the danger of residual microbes being left behind.

Images